Preventive and therapeutic reduction of amyloid deposition and behavioral impairments in a model of Alzheimer's disease by whole blood exchange

被引:20
|
作者
Urayama, Akihiko [1 ]
Moreno-Gonzalez, Ines [1 ,2 ]
Morales-Scheihing, Diego [1 ]
Kharat, Vineetkumar [1 ]
Pritzkow, Sandra [1 ]
Soto, Claudio [1 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Mitchell Ctr Alzheimers Dis & Related Brain Disor, Dept Neurol, McGovern Med Sch, Houston, TX 77030 USA
[2] Univ Malaga, Networking Res Ctr Neurodegenerat Dis CIBERNED, Inst Invest Biomed Malaga IBIMA, Dept Cell Biol Genet & Physiol,Fac Sci, Malaga, Spain
关键词
BETA-PROTEIN; MOUSE MODEL; BRAIN-BARRIER; PLASMA; CLEARANCE; PEPTIDE; ALBUMIN; PLAQUES; BURDEN; CNS;
D O I
10.1038/s41380-022-01679-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is the major form of dementia in the elderly population. The main neuropathological changes in AD patients are neuronal death, synaptic alterations, brain inflammation, and the presence of cerebral protein aggregates in the form of amyloid plaques and neurofibrillary tangles. Compelling evidence suggests that the misfolding, aggregation, and cerebral deposition of amyloid-beta (A ss) plays a central role in the disease. Thus, prevention and removal of misfolded protein aggregates is considered a promising strategy to treat AD. In the present study, we describe that the development of cerebral amyloid plaques in a transgenic mice model of AD (Tg2576) was significantly reduced by 40-80% through exchanging whole blood with normal blood from wild type mice having the same genetic background. Importantly, such reduction resulted in improvement in spatial memory performance in aged Tg2576 mice. The exact mechanism by which blood exchange reduces amyloid pathology and improves memory is presently unknown, but measurements of A ss in plasma soon after blood exchange suggest that mobilization of A ss from the brain to blood may be implicated. Our results suggest that a target for AD therapy may exist in the peripheral circulation, which could open a novel disease-modifying intervention for AD.
引用
收藏
页码:4285 / 4296
页数:12
相关论文
共 50 条
  • [21] Functionally distinct pericyte subsets differently regulate amyloid-β deposition in patients with Alzheimer's disease
    Bohannon, Diana G.
    Long, Danielle
    Okhravi, Hamid R.
    Lee, Sunhee C.
    De Jesus, Christopher Lawrence
    Neubert, Thomas A.
    Rostagno, Agueda A.
    Ghiso, Jorge A.
    Kim, Woong-Ki
    BRAIN PATHOLOGY, 2024,
  • [22] Apolipoprotein E, amyloid-β clearance and therapeutic opportunities in Alzheimer's disease
    Kline, Adam
    ALZHEIMERS RESEARCH & THERAPY, 2012, 4 (04):
  • [23] A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease
    Kitaguchi, Nobuya
    Hasegawa, Midori
    Ito, Shinji
    Kawaguchi, Kazunori
    Hiki, Yoshiyuki
    Nakai, Sigeru
    Suzuki, Nobuo
    Shimano, Yasunobu
    Ishida, Osamu
    Kushimoto, Hiroko
    Kato, Masao
    Koide, Sigehisa
    Kanayama, Kyoko
    Kato, Takashi
    Ito, Kengo
    Takahashi, Hiroshi
    Mutoh, Tatsuro
    Sugiyama, Satoshi
    Yuzawa, Yukio
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (11) : 1593 - 1607
  • [24] Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice
    Di Meco, Antonio
    Lauretti, Elisabetta
    Vagnozzi, Alana N.
    Pratico, Domenico
    NEUROBIOLOGY OF AGING, 2014, 35 (11) : 2458 - 2464
  • [25] Genetic variability in response to amyloid beta deposition influences Alzheimer's disease risk
    Salih, Dervis A.
    Bayram, Sevinc
    Guelfi, Sebastian
    Reynolds, Regina H.
    Shoai, Maryam
    Ryten, Mina
    Brenton, Jonathan W.
    Zhang, David
    Matarin, Mar
    Botia, Juan A.
    Shah, Runil
    Brookes, Keeley J.
    Guetta-Baranes, Tamar
    Morgan, Kevin
    Bellou, Eftychia
    Cummings, Damian M.
    Escott-Price, Valentina
    Hardy, John
    BRAIN COMMUNICATIONS, 2019, 1 (01)
  • [26] ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals
    Ordonez-Gutierrez, Lara
    Posado-Fernandez, Adrian
    Ahmadvand, Davoud
    Lettiero, Barbara
    Wu, Linping
    Anton, Marta
    Flores, Orfeu
    Moghimi, Seyed Moein
    Wandosell, Francisco
    BIOMATERIALS, 2017, 112 : 141 - 152
  • [27] Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease
    Menendez-Gonzalez, Manuel
    Padilla-Zambrano, Huber S.
    Alvarez, Gabriel
    Capetillo-Zarate, Estibaliz
    Tomas-Zapico, Cristina
    Costa, Agustin
    FRONTIERS IN AGING NEUROSCIENCE, 2018, 10
  • [28] Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study
    Kjeldsen, Pernille L.
    Parbo, Peter
    Hansen, Kim, V
    Aanerud, Joel F. A.
    Ismail, Rola
    Nissen, Peter H.
    Dalby, Rikke B.
    Damholdt, Malene F.
    Borghammer, Per
    Brooks, David J.
    AGING BRAIN, 2022, 2
  • [29] Migration of blood cells to β-amyloid plaques in Alzheimer's disease
    Hohsfield, Lindsay A.
    Humpel, Christian
    EXPERIMENTAL GERONTOLOGY, 2015, 65 : 8 - 15
  • [30] Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease
    Minami, S. Sakura
    Sidahmed, Elkhansa
    Aid, Saba
    Shimoji, Mika
    Niikura, Takako
    Mocchetti, Italo
    Rebeck, G. William
    Prendergast, Jay S.
    Dealwis, Chris
    Wetzel, Ronald
    Bosetti, Francesca
    Matsuoka, Yasuji
    Hoe, Hyang-Sook
    Turner, R. Scott
    JOURNAL OF NEUROINFLAMMATION, 2010, 7